To the Editor We welcome the recent study by Stolmeier et al1 that addresses the problem of laboratory monitoring for terbinafine and griseofulvin in adults and children, and we agree with their conclusion for terbinafine. We also have recently addressed the utility of monitoring liver function tests for terbinafine.2 Our conclusion was that monitoring does not work, primarily because the terbinafine-induced liver injury has an unpredictable and rapid onset and can occur at virtually any point within the first 2 months of treatment. It is also not necessary because the patients are clearly symptomatic at the very beginning of the reaction. Thus, we concluded that warning patients of the symptoms of acute liver injury and telling them to stop taking the medication and seek medical care when these symptoms occur is the best physicians can do.
Albrecht J, Kramer ON. Methodology of Evaluating the Laboratory Monitoring of Terbinafine Therapy. JAMA Dermatol. 2019;155(6):756. doi:10.1001/jamadermatol.2019.0360
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: